DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells. The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the tr

Trial Details

NCT ID
NCT07288112
Phase
PHASE1 / PHASE2
Sponsor
Diakonos Oncology Corporation
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • DOC1021
  • Tumor resection
  • pIFN (peginterferon alfa-2a)
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and avail-ability for the duration of the study
  • Age 18 years or older
  • Patients diagnosed with unresectable or metastatic melanoma and progressed following ≥1 prior systemic therapy including anti-PD-1 (i.e., refractor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →